Blog

ctDNA’s evolving role in cancer treatment

Photo taken from www.news-medical.net

Aug 6, 2024, 01:55

ctDNA’s evolving role in cancer treatment

Yüksel Ürün shared on X:

“The NCI Workshop highlighted ctDNA’s evolving role in cancer treatment. From predicting drug responses to monitoring minimal residual disease, ctDNA offers promising avenues for precision oncology.”

NCI Workshop on ctDNA in Cancer Treatment and Clinical Care

Authors: Brian S Sorg, Jung S Byun, V Anne Westbrook, James V Tricoli, James H Doroshow, Lyndsay N Harris.

ctDNA's evolving role in cancer treatment

Source: Yüksel Ürün/X

Other posts featuring Yüksel Ürün on OncoDaily.

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

Brian S Sorg cancer cancer monitoring cancer precision medicine cancer treatment ctDNA Drug Response Prediction Genetic Biomarkers James H Doroshow James V. Tricoli Jung S Byun Lyndsay N. Harris Minimal Residual Disease NCI Workshop OncoDaily Oncology oncology research Precision Oncology V Anne Westbrook

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer